Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Empagliflozin on Functional Capacity in HFpEF
NCT05139472Phase 4Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by UT Southwestern Medical Center. Started Nov 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05139472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139472.